{"nctId":"NCT00283686","briefTitle":"HALT Progression of Polycystic Kidney Disease Study A","startDateStruct":{"date":"2006-01","type":"ACTUAL"},"conditions":["Kidney, Polycystic"],"count":558,"armGroups":[{"label":"Study A, Arm 1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Lisinopril","Drug: Telmisartan","Other: Standard Blood Pressure Control"]},{"label":"Study A, Arm 2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Lisinopril","Drug: Telmisartan","Other: Low Blood Pressure Control"]},{"label":"Study A, Arm 3","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Lisinopril","Drug: Placebo","Other: Standard Blood Pressure Control"]},{"label":"Study A, Arm 4","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Lisinopril","Drug: Placebo","Other: Low Blood Pressure Control"]}],"interventions":[{"name":"Lisinopril","otherNames":["ACE-I","ACE","Ace-Inhibitor"]},{"name":"Telmisartan","otherNames":["ARB"]},{"name":"Placebo","otherNames":[]},{"name":"Standard Blood Pressure Control","otherNames":["blood pressure control"]},{"name":"Low Blood Pressure Control","otherNames":["blood pressure control"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of ADPKD.\n* Age 15-49 (Study A); Age 18-64 (Study B).\n* GFR \\>60 mL/min/1.73 m2 (Study A); GFR 25-60 mL/min/1.73 m2 (Study B).\n* BP ≥130/80 or receiving treatment for hypertension.\n* Informed Consent.\n\nExclusion Criteria:\n\n* Pregnant/intention to become pregnant in 4-6 yrs.\n* Documented renal vascular disease.\n* Spot urine albumin-to-creatinine ratio of \\>0.5 (Study A) or ≥1.0 (Study B) and/or findings suggestive of kidney disease other than ADPKD.\n* Diabetes requiring insulin or oral hypoglycemic agents / fasting serum glucose of \\>126 mg/dl / random non-fasting glucose of \\>200 mg/dl.\n* Serum potassium \\>5.5 milliequivalent per liter (mEq/L) for participants currently on ACE-I or ARB; \\>5.0 mEq/L for participants not currently on ACE-I or ARB.\n* History of angioneurotic edema or other absolute contraindication for ACE-I or ARB. Intolerable cough associated with ACE-I is defined as a cough developing within six months of initiation of ACE-I in the absence of other causes and resolving upon discontinuation of the ACE-I.\n* Indication (other than hypertension) for β-blocker or calcium channel blocker therapy (e.g. angina, past myocardial infarction, arrhythmia), unless approved by the site principal investigator. (PI may choose to accept an individual who is on only a small dose of one of these agents and would otherwise be eligible.)\n* Systemic illness necessitating nonsteroidal antiinflammatory drugs (NSAIDs), immunosuppressant or immunomodulatory medications.\n* Systemic illness with renal involvement.\n* Hospitalized for acute illness in past 2 months.\n* Life expectancy \\<2 years.\n* History of non-compliance.\n* Unclipped cerebral aneurysm \\>7mm diameter.\n* Creatine supplements within 3 months of screening visit.\n* Congenital absence of a kidney (also total nephrectomy for Study B).\n* Known allergy to sorbitol or sodium polystyrene sulfonate.\n* Exclusions specific to magnetic resonance imaging (Study A).","healthyVolunteers":false,"sex":"ALL","minimumAge":"15 Years","maximumAge":"64 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Study A: Percent Annual Change in Total Kidney Volume","description":"Annual percentage change in total kidney volume as assessed by abdominal magnetic resonance imaging (MRI) at baseline, 2 years, 4 years, and 5 years follow-up.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":null},{"groupId":"OG001","value":"6.2","spread":null},{"groupId":"OG002","value":"5.6","spread":null},{"groupId":"OG003","value":"6.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Kidney Function (eGFR)","description":"The estimated GFR was calculated by means of the Chronic Kidney Disease Epidemiology Collaboration equation with the use of central serum creatinine measurements.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","spread":null},{"groupId":"OG001","value":"-2.9","spread":null},{"groupId":"OG002","value":"-2.9","spread":null},{"groupId":"OG003","value":"-3.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Albuminuria","description":"Urine albumin excretion, centrally processed from 24 hour urine collection","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":null},{"groupId":"OG001","value":"-0.4","spread":null},{"groupId":"OG002","value":"-3.8","spread":null},{"groupId":"OG003","value":"2.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Aldosterone","description":"Urinary aldosterone excretion, centrally processed, 24 hour urine collection","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.5","spread":null},{"groupId":"OG001","value":"-7.3","spread":null},{"groupId":"OG002","value":"-8.5","spread":null},{"groupId":"OG003","value":"-7.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Left Ventricular Mass Index","description":"Left ventricular mass index (g/m\\^2) measured by MRI, centrally reviewed and measured","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.91","spread":null},{"groupId":"OG001","value":"-0.83","spread":null},{"groupId":"OG002","value":"-1.17","spread":null},{"groupId":"OG003","value":"-0.57","spread":null}]}]}]},{"type":"SECONDARY","title":"Renal Blood Flow","description":"renal blood flow (mL/min/1.73 m\\^2) from MRI, centrally reviewed and measured. This outcome was more difficult to measure resulting in more missing data than other MRI outcomes such as total kidney volume (TKV) and left ventricular mass index (LVMI).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.6","spread":null},{"groupId":"OG001","value":"-9.5","spread":null},{"groupId":"OG002","value":"-7.6","spread":null},{"groupId":"OG003","value":"-8.5","spread":null}]}]}]},{"type":"SECONDARY","title":"All-Cause Hospitalizations","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"128","spread":null},{"groupId":"OG002","value":"93","spread":null},{"groupId":"OG003","value":"120","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life Physical Component Summary","description":"Short Form-36 Quality of Life Physical Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome)","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":null},{"groupId":"OG001","value":"-.23","spread":null},{"groupId":"OG002","value":"-0.17","spread":null},{"groupId":"OG003","value":"-0.30","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life Mental Component Summary","description":"Short Form-36 Quality of LIfe Mental Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome)","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":null},{"groupId":"OG001","value":"-0.06","spread":null},{"groupId":"OG002","value":"-0.05","spread":null},{"groupId":"OG003","value":"0.18","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":58,"n":273},"commonTop":["Acute kidney injury","Hyperkalemia"]}}}